4.4 Review

Vitamin D and colon cancer

Journal

ENDOCRINE-RELATED CANCER
Volume 19, Issue 3, Pages R51-R71

Publisher

BIOSCIENTIFICA LTD
DOI: 10.1530/ERC-11-0388

Keywords

-

Funding

  1. Ministerio de Ciencia e Innovacion of Spain [SAF2010-18302]
  2. Fondo Europeo de Desarrollo Regional-Instituto de Salud Carlos III [RD06/0020/0009]
  3. Comunidad de Madrid [S2011/BMD-2344, Colomics2]

Ask authors/readers for more resources

The most active vitamin D metabolite, 1 alpha,25-dihydroxyvitamin D-3 (1,25(OH)(2)D-3), is a pleiotropic hormone with wide regulatory actions. Classically, vitamin D deficiency was known to alter calcium and phosphate metabolism and bone biology. In addition, recent epidemiological and experimental studies support the association of vitamin D deficiency with a large variety of human diseases, and particularly with the high risk of colorectal cancer. By regulating the expression of many genes via several mechanisms, 1,25(OH)(2)D-3 induces differentiation, controls the detoxification metabolism and cell phenotype, sensitises cells to apoptosis and inhibits the proliferation of cultured human colon carcinoma cells. Consistently, 1,25(OH)(2)D-3 and several of its analogues decrease intestinal tumourigenesis in animal models. Molecular, genetic and clinical data in humans are scarce but they suggest that vitamin D is protective against colon cancer. Clearly, the available evidence warrants new, well-designed, large-scale trials to clarify the role of vitamin D in the prevention and/or therapy of this important neoplasia. Endocrine-Related Cancer (2012) 19 R51-R71

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available